Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition

被引:24
作者
Semenov, Oleg [1 ]
Daks, Alexandra [1 ]
Fedorova, Olga [1 ]
Shuvalov, Oleg [1 ]
Barlev, Nickolai A. [1 ,2 ,3 ]
机构
[1] Inst Cytol RAS, Regulat Gene Express Lab, St Petersburg, Russia
[2] Moscow Inst Phys & Technol, Lab Intracellular Signalling, Dolgoprudnyi, Russia
[3] Inst Biomed Chem, Grp Targeted Delivery Mech Nanosyst, Moscow, Russia
基金
俄罗斯科学基金会;
关键词
p53; wild-type p53; mutant p53; EMT; epithelial to mesenchymal transition; microRNA; epigenetic regulation; GLUCOSE-METABOLISM; SIGNALING PATHWAY; TARGETING ZEB1; CELL INVASION; FEEDBACK LOOP; CANCER CELLS; EXPRESSION; GROWTH; EMT; SNAIL;
D O I
10.3389/fmolb.2022.928399
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The central role of an aberrantly activated EMT program in defining the critical features of aggressive carcinomas is well documented and includes cell plasticity, metastatic dissemination, drug resistance, and cancer stem cell-like phenotypes. The p53 tumor suppressor is critical for leashing off all the features mentioned above. On the molecular level, the suppression of these effects is exerted by p53 via regulation of its target genes, whose products are involved in cell cycle, apoptosis, autophagy, DNA repair, and interactions with immune cells. Importantly, a set of specific mutations in the TP53 gene (named Gain-of-Function mutations) converts this tumor suppressor into an oncogene. In this review, we attempted to contrast different regulatory roles of wild-type and mutant p53 in the multi-faceted process of EMT.
引用
收藏
页数:11
相关论文
共 96 条
[1]   A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis [J].
Adorno, Maddalena ;
Cordenonsi, Michelangelo ;
Montagner, Marco ;
Dupont, Sirio ;
Wong, Christine ;
Hann, Byron ;
Solari, Aldo ;
Bobisse, Sara ;
Rondina, Maria Beatrice ;
Guzzardo, Vincenza ;
Parenti, Anna R. ;
Rosato, Antonio ;
Bicciato, Silvio ;
Balmain, Allan ;
Piccolo, Stefano .
CELL, 2009, 137 (01) :87-98
[2]  
Alam Farheen, 2017, Tumour Biol, V39, p1010428317714634, DOI [10.1177/1010428317714634, 10.1177/1010428317714634]
[3]   DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53 [J].
Alam, S. K. ;
Yadav, V. K. ;
Bajaj, S. ;
Datta, A. ;
Dutta, S. K. ;
Bhattacharyya, M. ;
Bhattacharya, S. ;
Debnath, S. ;
Roy, S. ;
Boardman, L. A. ;
Smyrk, T. C. ;
Molina, J. R. ;
Chakrabarti, S. ;
Chowdhury, S. ;
Mukhopadhyay, D. ;
Roychoudhury, S. .
CELL DEATH AND DIFFERENTIATION, 2016, 23 (04) :707-722
[4]   Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches [J].
Alvarado-Ortiz, Eduardo ;
de la Cruz-Lopez, Karen Griselda ;
Becerril-Rico, Jared ;
Sarabia-Sanchez, Miguel Angel ;
Ortiz-Sanchez, Elizabeth ;
Garcia-Carranca, Alejandro .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 8
[5]   Genetic modulation of hypoxia induced gene expression and angiogenesis: Relevance to brain tumors [J].
Brat, DJ ;
Kaur, B ;
Van Meir, EG .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2003, 8 :D100-D116
[6]   Targeting mutant p53 for efficient cancer therapy [J].
Bykov, Vladimir J. N. ;
Eriksson, Sofi E. ;
Bianchi, Julie ;
Wiman, Klas G. .
NATURE REVIEWS CANCER, 2018, 18 (02) :89-102
[7]   HPV-p53-miR-34a axis in HPV-associated cancers [J].
Chen, Jiezhong ;
Zhao, Kong-Nan .
ANNALS OF TRANSLATIONAL MEDICINE, 2015, 3 (21)
[8]   AP4 activates cell migration and EMT mediated by p53 in MDA-MB-231 breast carcinoma cells [J].
Chen, Shaopeng ;
Chiu, Sung-Kay .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2015, 407 (1-2) :57-68
[9]   Urolithin A Inhibits Epithelial-Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway [J].
Cheng, Feng ;
Dou, Jintao ;
Zhang, Yong ;
Wang, Xiang ;
Wei, Huijun ;
Zhang, Zhijian ;
Cao, Yuxiang ;
Wu, Zhihao .
ONCOTARGETS AND THERAPY, 2021, 14 :3199-3208
[10]   NF2 blocks Snail-mediated p53 suppression in mesothelioma [J].
Cho, Jung-Hyun ;
Lee, Su-Jin ;
Oh, Ah-Young ;
Yoon, Min-Ho ;
Woo, Tae-Geun ;
Park, Bum-Joon .
ONCOTARGET, 2015, 6 (12) :10073-10085